Results from a phase III clinical trial (NCT02017717) comparing the efficacy of Nivolumab monotherapy versus bevacizumab in improving survival rates of patients with recurrent glioblastoma showed that the subgroup of glioblastoma patients with methylated MGMT promoters and no baseline corticosteroid dependence may be most likely to benefit from immune checkpoint inhibition (71, 72). This evidence concerns the gene MGMT and glioblastoma.